- Home
- ASIX vs CVAC Comparison
ASIX vs CVAC Comparison
Compare ASIX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASIX
- CVAC
- Stock Information
- Founded
- ASIX 2016
- CVAC 2000
- Country
- ASIX United States
- CVAC Germany
- Employees
- ASIX N/A
- CVAC N/A
- Industry
- ASIX Major Chemicals
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ASIX Industrials
- CVAC Health Care
- Exchange
- ASIX Nasdaq
- CVAC Nasdaq
- Market Cap
- ASIX 654.2M
- CVAC 764.4M
- IPO Year
- ASIX N/A
- CVAC 2020
- Fundamental
- Price
- ASIX $23.45
- CVAC $5.44
- Analyst Decision
- ASIX Buy
- CVAC Buy
- Analyst Count
- ASIX 1
- CVAC 3
- Target Price
- ASIX $32.00
- CVAC $9.00
- AVG Volume (30 Days)
- ASIX 123.9K
- CVAC 2.1M
- Earning Date
- ASIX 08-01-2025
- CVAC 08-14-2025
- Dividend Yield
- ASIX 2.71%
- CVAC N/A
- EPS Growth
- ASIX 3682.26
- CVAC N/A
- EPS
- ASIX 3.11
- CVAC 0.87
- Revenue
- ASIX $1,558,519,000.00
- CVAC $566,039,775.00
- Revenue This Year
- ASIX $7.41
- CVAC N/A
- Revenue Next Year
- ASIX $4.60
- CVAC $24.04
- P/E Ratio
- ASIX $7.63
- CVAC $6.34
- Revenue Growth
- ASIX 6.03
- CVAC 787.60
- 52 Week Low
- ASIX $18.44
- CVAC $2.37
- 52 Week High
- ASIX $33.00
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- ASIX 46.93
- CVAC 68.03
- Support Level
- ASIX $23.86
- CVAC $4.07
- Resistance Level
- ASIX $24.56
- CVAC $5.58
- Average True Range (ATR)
- ASIX 0.46
- CVAC 0.20
- MACD
- ASIX -0.12
- CVAC 0.07
- Stochastic Oscillator
- ASIX 11.20
- CVAC 83.08
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.